RS

Real Estate Split Corp. Announces Successful Overnight Offering  

Retrieved on: 
Thursday, September 21, 2023
Treasury, BMO Capital Markets, TD, Toronto Stock Exchange, Marketing, Sale, RBC Capital Markets, RS, TSX, Class B share, Scotiabank, Security (finance), Life insurance

TORONTO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Middlefield Group, on behalf of Real Estate Split Corp. (TSX: RS and RS.PR.A) (the “Company”), is pleased to announce a successful overnight treasury offering of class A and preferred shares (the “Class A Shares” and “Preferred Shares”, respectively). Gross proceeds of the offering are expected to be approximately $13.3 million.

Key Points: 
  • TORONTO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Middlefield Group, on behalf of Real Estate Split Corp. (TSX: RS and RS.PR.A) (the “Company”), is pleased to announce a successful overnight treasury offering of class A and preferred shares (the “Class A Shares” and “Preferred Shares”, respectively).
  • Gross proceeds of the offering are expected to be approximately $13.3 million.
  • The offering is expected to close on or about Thursday, September 28, 2023 and is subject to certain closing conditions including approval by the Toronto Stock Exchange.
  • The Company has been designed to provide investors with a diversified, actively managed, high conviction portfolio comprised of securities of leading North American real estate companies.

Real Estate Split Corp. Announces Overnight Offering

Retrieved on: 
Wednesday, September 20, 2023
Treasury, Toronto Stock Exchange, Marketing, Sale, RBC Capital Markets, RS, TSX, Class B share, Scotiabank, Security (finance)

TORONTO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Middlefield Group, on behalf of Real Estate Split Corp. (TSX: RS and RS.PR.A) (the “Company”), is pleased to announce that the Company is undertaking an overnight treasury offering of class A and preferred shares (the “Class A Shares” and “Preferred Shares”, respectively).

Key Points: 
  • TORONTO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Middlefield Group, on behalf of Real Estate Split Corp. (TSX: RS and RS.PR.A) (the “Company”), is pleased to announce that the Company is undertaking an overnight treasury offering of class A and preferred shares (the “Class A Shares” and “Preferred Shares”, respectively).
  • The sales period for this overnight offering will end at 9:00 a.m. (ET) on Thursday, September 21, 2023.
  • The offering is expected to close on or about September 28, 2023 and is subject to certain closing conditions including approval by the Toronto Stock Exchange (“TSX”).
  • The Company has been designed to provide investors with a diversified, actively managed, high conviction portfolio comprised of securities of leading North American real estate companies.

Innovative technology from ABT Sportsline for even more power: Up to 1000 hp for the special models Audi RS 6 and RS 7 Legacy Edition

Retrieved on: 
Thursday, September 14, 2023
Abt Sportsline, Oxygen, Audi RS 6, Carbon, Volkswagen Group, Indirect, Ethanol, RS, IWI, Chevrolet Turbo-Air 6 engine, AEC, Twin-turbo, HP, Gasoline

"The IWI technology offers us the thermodynamic advantages to be able to display the most enduring power output in these performance regions.

Key Points: 
  • "The IWI technology offers us the thermodynamic advantages to be able to display the most enduring power output in these performance regions.
  • The new IWI system is activated via the RS buttons on the steering wheel of the RS 6 LE and RS 7 LE.
  • Additional components from ABT Sportsline are necessary for the 1000 hp conversion.
  • In addition, ABT Sportsline gave the two vehicles special intercoolers with enlarged air intakes in the front apron.

Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica

Retrieved on: 
Thursday, September 14, 2023
Research, Technology, Medical Devices, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Artificial Intelligence, Learning, International Association of Students in Agricultural and Related Sciences, Therapy, Senior, Multimedia, Related, Doctor of Philosophy, Autoimmunity, Logica, RS, Artificial intelligence, Drug discovery, Biology, ADME, CRL, AI, IND, NYSE, Pharmacology, Inflammation, Pharmaceutical industry, Management

Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply Logica™ across several previously undrugged targets in the RS portfolio.

Key Points: 
  • Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program collaboration agreement to apply Logica™ across several previously undrugged targets in the RS portfolio.
  • Logica is an Artificial Intelligence (AI) powered drug solution that translates biological insights into optimized assets.
  • “Partnering with the team at Related Sciences, we are excited to deploy Logica in the hunt for first-in-class therapeutics,” said Julie Frearson, PhD, Senior Vice President and Chief Scientific Officer, Charles River.
  • Logica is offered as a fully managed, risk-sharing model, with most of the client cost tied to success.

RS Oncology Announces New Preclinical Data Show RSO-021 May Block and/or Reverse the Progression of Aggressive Mesotheliomas, Improving Druggability

Retrieved on: 
Wednesday, September 13, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Malignant pleural effusion, Tissue, Partnership, AACR, University, Spatial analysis, Neoplasm, Mesothelioma, Survival, EMT, Lung cancer, Multimedia, Photograph, Drug resistance, Oxidative stress, Glycolysis, Patient, Nature, Lunch, RS, University of Leicester, Hypoxia, Conference, Leicester, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230912702236/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230912702236/en/
    “Sarcomatoid tumors are highly resistant to anti-cancer therapies, and many patients run out of available treatment options.
  • Our findings here might have unveiled a druggable ‘Achilles Heel’ against this terrible disease,” said Dr. Fennell, presenting author on the study.
  • (Photo courtesy of George Naumov)
    Mesotheliomas can transform from a less aggressive epithelioid malignancy to a more aggressive sarcomatoid form.
  • RSO-021 treatment reversed the gene signatures associated with epithelial-to-sarcomatoid transition, including downregulation of hypoxia, glycolysis, and epithelial-to-mesenchymal transition (EMT)-associated genes.

RS Oncology Announces Completion of First-in-Human Phase 1 Clinical Trial of RSO-021, a Novel Irreversible Inhibitor of Mitochondrial PRX3

Retrieved on: 
Tuesday, September 12, 2023
Biotechnology, Infectious Diseases, Health, Radiology, Oncology, Lung, RS, Mesothelioma, Cancer, Patient, Caregiver, Safety, Pharmaceutical industry

RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, today announced the completion of the Phase 1 dose escalation portion of the MITOPE study ( NCT05278975 ).

Key Points: 
  • RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, today announced the completion of the Phase 1 dose escalation portion of the MITOPE study ( NCT05278975 ).
  • The United Kingdom-based multicenter study met its primary objective of evaluating the safety and tolerability of RSO-021, a novel irreversible inhibitor of mitochondrial PRX3, in patients with malignant pleural mesothelioma and local disease affecting the lining of the lungs.
  • These patients also had fluid on their lungs due to the cancer, which had failed to respond to at least one prior treatment.
  • "Concluding Phase 1 is a significant accomplishment towards bringing a potential new therapy to patients suffering from mesothelioma and other cancers of the lung,” said Jarrett Duncan, CEO of RS Oncology.

RS Announces the Availability of the New DiaForce 120mm Diagonal Compact Fan From ebm-papst

Retrieved on: 
Wednesday, September 13, 2023
Ebm-papst, Pressure, LSE, Housing, Greentech, Noise, Electronics, Internet of things, Temperature, ANSI, OSHA, RS Group, NEBS, RS, RS Group plc, AI, ETSI, Safety, Electric motor

FORT WORTH, Texas, Sept. 13, 2023 /PRNewswire/ -- RS, a trading brand of RS Group plc (LSE: RS1), a global provider of industrial product and service solutions, is stocking the revolutionary new DiaForce 120mm diagonal compact fans from ebm-papst. The new DiaForce fans feature an innovative design that combines the high airflow volume of an axial fan with the high static pressure capabilities of a centrifugal fan. This inventive combination delivers the high performance of counter-rotating axial fans with less noise and significant power efficiency improvements to satisfy the challenging cooling demands of evolving digital connectivity applications.

Key Points: 
  • FORT WORTH, Texas, Sept. 13, 2023 /PRNewswire/ -- RS , a trading brand of RS Group plc (LSE: RS1), a global provider of industrial product and service solutions, is stocking the revolutionary new DiaForce 120mm diagonal compact fans from ebm-papst.
  • The new DiaForce fans feature an innovative design that combines the high airflow volume of an axial fan with the high static pressure capabilities of a centrifugal fan.
  • ebm-papst DiaForce fans deliver up to 50% more air performance than the best single-stage compact axial fans available.
  • To learn more about ebm-papst's new DiaForce compact diagonal fans for demanding digital connectivity applications, please click the embedded links, contact your local RS representative at 1.866.433.5722, or reach out to our technical support team .

CHICAGO AUTOMOBILE TRADE ASSOCIATION HOSTS SECOND ANNUAL "CHICAGO DRIVES ELECTRIC" EV TEST DRIVE AND EDUCATIONAL EVENT: SEPT. 29 - OCT. 1

Retrieved on: 
Thursday, September 7, 2023
Ford Mustang Mach-E, Commonwealth Edison, 2024 Democratic National Convention, EV9, EV, McCormick Place, Nissan Ariya, Volvo, Anxiety, CATA, Ford, Chicago Auto Show, SUV, EVS, Kia, Volkswagen, Hyundai, Alfa Romeo, Toyota Prius, RS, Ford Mustang, Chrysler, Jeep, Interview, Car rental, Nightclub, Chicago metropolitan area, Cars.com, Nissan, Cadillac, Audi

OAKBROOK TERRACE, Ill. , Sept. 7, 2023 /PRNewswire/ -- The Chicago Automobile Trade Association (CATA), the area's new-car dealer association and producer of the Chicago Auto Show, announced the return of Chicago Drives Electric, to be held Sept. 29-Oct. 1.

Key Points: 
  • OAKBROOK TERRACE, Ill. , Sept. 7, 2023 /PRNewswire/ -- The Chicago Automobile Trade Association (CATA), the area's new-car dealer association and producer of the Chicago Auto Show, announced the return of Chicago Drives Electric, to be held Sept. 29-Oct. 1.
  • Event organizers are also bringing in a variety of experts to help break down the various aspects of EV ownership.
  • On-hand experts will include representatives from Cars.com, CHARGE Enterprises, ComEd, Drive Chicago and Powering Chicago.
  • "This is a testament to the continued momentum behind Chicago Drives Electric as auto manufacturers debut the latest models and new technology."

RS Adds Three New Quality-Centric Component Suppliers

Retrieved on: 
Thursday, September 7, 2023
LSE, EU, DC, VOC, AC, Amp, 1986 California Proposition 65, LED, RS Group, ODC, Asbestos, REACH, RS, RS Group plc, SCI, POP, Restriction of Hazardous Substances Directive, Engine Components Inc., Electric motor

FORT WORTH, Texas, Sept. 7, 2023 /PRNewswire/ -- RS, a trading brand of RS Group plc (LSE: RS1), a global provider of industrial product and service solutions, again expanded its product offering, adding three new quality-centric component suppliers to its line card of more than 700 trusted suppliers.

Key Points: 
  • RS offers a variety of Adam Tech component solutions, including connectors, cable assemblies, cable glands, and battery holders.
  • It was established as a new independent component division of Triad Partners, LLC in 2018.
  • RS offers a variety of Switch Components solutions, including switches, connectors, LED indicators, and industrial controls such as solenoids and digital volt and amp meters.
  • To learn more about these suppliers and their products, please click the embedded links above, contact your local RS representative at 1.866.433.5722, or reach out to our technical support team .

RS BioTherapeutics and National Institutes of Health Execute Research Collaboration Agreement to Evaluate Prevention and Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, August 29, 2023
COPD, Gestational sac, Research, American Thoracic Society, National Institute on Alcohol Abuse and Alcoholism, Bangladesh Technical Education Board, Fibrosis, MD, RS, Diagnosis, IPF, Death, NIH, Idiopathic pulmonary fibrosis, NIAAA, Respiratory failure, Global Research Collaboration for Infectious Disease Preparedness, Conditional sentence, Disease, Pharmaceutical industry, Medical imaging, Alcoholism

According to NIH , idiopathic pulmonary fibrosis (IPF) is a serious, chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs.

Key Points: 
  • According to NIH , idiopathic pulmonary fibrosis (IPF) is a serious, chronic disease that affects the tissue surrounding the air sacs, or alveoli, in the lungs.
  • This condition develops when lung tissue becomes thick and stiff for unknown reasons.
  • Over time, these changes can cause permanent scarring in the lungs, called fibrosis, that makes it progressively more difficult to breathe.
  • Commentating on the Research Collaboration Agreement with NIH, Michelle L. Shuffett, MD, Chief Medical Officer of RS BioTherapeutics said, “We are incredibly pleased to be working in a collaborative manner with NIH to evaluate our cornerstone compound, RSBT-001, in an animal pulmonary fibrosis model.